TICKERNERD
Menu
CINGCINGHealthcare · Biotechnology

CING Stock Forecast: Cingulate, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$5.55

The 4 Wall Street analysts covering Cingulate, Inc. hold a median 12-month price target of $20 — +260.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 28 of 100 as at 21 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$77.5M
Ticker Nerd rank
28 / 100
Median analyst target
$20
Analysts covering
4
Ticker Nerd rank

CING stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Cingulate, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Aug 2026
28 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
78
Accruals
58
Revisions
55
Quality
36
Issuance
34
Volatility
32
Momentum
31
Growth
26
Value
25

Size (78): Smaller than most of the companies we track.

Value (25): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CING stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CING, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $8Median $20High $44

The green dot is the last close — the median target sits +260.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
20 Aug 2026Ascendiant CapitalMaintainsBuy$52 → $44
8 June 2026Ascendiant CapitalMaintainsBuy$55 → $52
26 May 2026HC Wainwright & Co.ReiteratesBuy—
8 Apr 2026Ascendiant CapitalMaintainsBuy—
23 Mar 2026Roth CapitalMaintainsBuy—
8 Dec 2025Ascendiant CapitalMaintainsBuy—
19 Nov 2025Roth CapitalMaintainsBuy—
15 Oct 2025Roth CapitalMaintainsBuy—
22 Aug 2025Ascendiant CapitalMaintainsBuy—
27 May 2025Ascendiant CapitalMaintainsBuy—
19 May 2025Roth CapitalMaintainsBuy—
21 Apr 2025Ascendiant CapitalMaintainsBuy—
6 Mar 2025HC Wainwright & Co.ReiteratesBuy—
30 Jan 2025HC Wainwright & Co.MaintainsBuy—
10 Jan 2025Roth MKMInitiatesBuy—
20 Nov 2024Maxim GroupUpgradeBuy—
5 Jan 2024HC Wainwright & Co.MaintainsBuy—
22 Dec 2023Laidlaw & Co.DowngradeHold—
19 Dec 2023Maxim GroupDowngradeHold—
18 Dec 2023Maxim GroupDowngradeHold—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CING appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

CING analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
2
Fundamentals

Cingulate, Inc. (CING) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.0×

Cheaper than 74% of US stocks

Price / sales
—
Price / book
15.4×

Cheaper than 7% of US stocks

EV / EBITDA
−2.3×

Cheaper than 72% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−198.7%

Higher than 7% of US stocks

Return on assets
−66.9%

Higher than 5% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

CING vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CINGCingulate, Inc.$77.5M
28
ELTXElicio Therapeutics, Inc.$79.9M
38
VRCAVerrica Pharmaceuticals, Inc.$82.8M
72
TELOTelomir Pharmaceuticals, Inc.$77.7M
13
ANVSAnnovis Bio, Inc.$77.4M
26
MAIAMAIA Biotechnology, Inc.$84.3M
20
DWTXDogwood Therapeutics, Inc.$84.6M
37

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Cingulate, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CING news & analysis

Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness

GlobeNewsWire · 13 Aug 2026positive

Cingulate Inc. reported its financial results for the quarter ended June 30, 2026, and provided an update on the chemistry, manufacturing, and controls (CMC) progress of CTx-1301 toward NDA resubmission and commercial readiness.

Why it matters — A CING watcher would care because the update on CTx-1301's CMC progress signals the company's path toward NDA resubmission and eventual commercialization of a lead pipeline product.

Cingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent Psychopharmacology

GlobeNewsWire · 30 July 2026positive

Cingulate announced that results from its Phase 3 ADHD trial for CTx-1301 have been published in the Journal of Child and Adolescent Psychopharmacology. The publication helps establish the efficacy and safety profile of CTx-1301 and reinforces the potential of Cingulate's Precision Timed Release platform technology.

Why it matters — A peer-reviewed publication of Phase 3 results adds external validation and credibility for CTx-1301's efficacy and safety data, which is a key milestone for Cingulate's lead candidate and its drug-delivery platform.

FAQ

Frequently asked questions about CING stock

What is the CING stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Cingulate, Inc. have a median 12-month price target of $20, with estimates ranging from $8 to $44. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CING stock a buy right now?

Of the 4 analysts covering Cingulate, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cingulate, Inc. 28 out of 100 across roughly 4,600 US stocks as at 21 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CING?

As at 21 Aug 2026, Cingulate, Inc. ranks 28 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (78 of 100).

Will CING stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +260.4% from the last close, and Ticker Nerd's factor model ranks Cingulate, Inc. 28 out of 100 as at 21 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CING stock forecast for 2030?

No analyst covering Cingulate, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CING are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $44 over the next 12 months.

What does Cingulate, Inc. do?

Cingulate Inc. is a clinical-stage biopharmaceutical company that develops pharmaceutical products using a proprietary precision timed-release drug delivery platform.

What is the latest news on CING?

The most recent item we track (GlobeNewsWire, 13 Aug 2026): "Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness". Cingulate Inc. reported its financial results for the quarter ended June 30, 2026, and provided an update on the chemistry, manufacturing, and controls (CMC) progress of CTx-1301 toward NDA resubmission and commercial readiness.

Company

About Cingulate, Inc.

Cingulate Inc. is a clinical-stage biopharmaceutical company that develops pharmaceutical products using a proprietary precision timed-release drug delivery platform. The company concentrates on treatments for attention deficit/hyperactivity disorder and anxiety, aiming to provide medications that deliver more consistent therapeutic coverage over the day while reducing the need for multiple daily doses. Its lead product candidate, CTx-1301 (dexmethylphenidate), is being developed for ADHD, and additional candidates such as CTx-2103 (buspirone) target anxiety and broader mental health conditions. By focusing on frequently diagnosed conditions that often have burdensome dosing regimens and variable outcomes, Cingulate seeks to address unmet needs in neuropsychiatric care. The company operates in the healthcare sector within the biotechnology industry and is headquartered in Kansas City, Kansas, in the United States.

CEO Dr. Shane J. Schaffer Pharm.D. · 14 employees · United States · https://www.cingulate.com